Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17428430 | 1.00 | MAOB (0.38) | MAOBCALM1CYP1A2 | |
| SCHEMBL29126087 | 0.89 | ALDH1A1 (0.35) | MAOB | |
| SCHEMBL29260847 | 0.85 | MAOB (0.32) | MAOB | |
| SCHEMBL21184213 | 0.85 | MAOB (0.32) | MAOB | |
| SCHEMBL7699281 | 0.85 | MAOB (0.32) | MAOB | |
| SCHEMBL4946678 | 0.85 | CA1 (0.33) | MAOB | |
| SCHEMBL4946673 | 0.85 | CA1 (0.33) | MAOB | |
| SCHEMBL10882646 | 0.85 | TLR8 (0.32) | — | |
| SCHEMBL5974388 | 0.84 | IDO1 (0.45) | MAOB | |
| SCHEMBL5974386 | 0.84 | IDO1 (0.45) | MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12006553-B2 | Companion diagnostics for mitochondrial inhibitors | LUNELLA BIOTECH, INC. (CA) | 2024-06-11 | — | — | US | disclosed |
| US-20200255902-A1 | COMPANION DIAGNOSTICS FOR MITOCHONDRIAL INHIBITORS | LUNELLA BIOTECH, INC. (CA) | 2020-08-13 | — | — | US | disclosed |
| EP-3624897-A1 | COMPANION DIAGNOSTICS FOR MITOCHONDRIAL INHIBITORS | Lunella Biotech, Inc. (CA) | 2020-03-25 | — | — | EP | disclosed |
| WO-2018213764-A1 | COMPANION DIAGNOSTICS FOR MITOCHONDRIAL INHIBITORS | LUNELLA BIOTECH, INC. (CA) | 2018-11-22 | — | — | WO | disclosed |
| US-7423168-B2 | Reacting allyl starting compound with oxygen nucleophilic agent in presence of transition metal catalyst and monodentate phosphite | MITSUBISHI CHEMICAL CORPORATION (JP) | 2008-09-09 | — | — | US | disclosed |
| US-7241857-B2 | Method for producing allyl compound, and ether or ester compound produced thereby | MITSUBISHI CHEMICAL CORPORATION (JP) | 2007-07-10 | — | — | US | disclosed |
| US-7173157-B2 | Method for producing an allyl compound | MITSUBISHI CHEMICAL CORPORATION (JP) | 2007-02-06 | — | — | US | disclosed |
| US-7119222-B2 | Method for producing allyl compound, and ether or ester compound produced thereby | MITSUBISHI CHEMICAL CORPORATION (JP) | 2006-10-10 | — | — | US | disclosed |
| US-20060106181-A1 | Method for producing allyl compound, and ether or ester compound produced thereby | MITSUBISHI CHEMICAL CORPORATION (JP) | 2006-05-18 | — | — | US | disclosed |
| US-20050075518-A1 | Method for producing allyl compound, and allyl compound produced thereby | MITSUBISHI CHEMICAL CORPORATION (JP) | 2005-04-07 | — | — | US | disclosed |
| US-20040147757-A1 | Method for producing allyl compound, and ether or ester compound produced thereby | MITSUBISHI CHEMICAL CORPORATION (JP) | 2004-07-29 | — | — | US | disclosed |
| US-20040092777-A1 | Method for producing allyl compound | MITSUBISHI CHEMICAL CORPORATION (JP) | 2004-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106181-A1 | Method for producing allyl compound, and ether or ester compound produced thereby | AGPAT5, TST, AGPAT2 | MAOB 2469/4885CALM1 4580/4885CYP1A2 486/4885 |
| US-20040147757-A1 | Method for producing allyl compound, and ether or ester compound produced thereby | AGPAT5, TST, AGPAT2 | MAOB 2469/4885CALM1 4580/4885CYP1A2 486/4885 |
| US-20040092777-A1 | Method for producing allyl compound | CCNT1, APEX1, REV1 | MAOB 3382/4885CALM1 3835/4885CYP1A2 1479/4885 |
| US-20050075518-A1 | Method for producing allyl compound, and allyl compound produced thereby | CCNT1, AOC3, ATL3 | MAOB 1689/4885CALM1 4634/4885CYP1A2 385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.